Postdoctoral Researcher
Kennziffer: 2025-0096
- Heidelberg
- Vollzeit
- Translational Medical Oncology at DKFZ and NCT Heidelberg
„Forschen für ein Leben ohne Krebs“ – das ist unsere Aufgabe am Deutschen Krebsforschungszentrum. Wir erforschen, wie Krebs entsteht, erfassen Krebsrisikofaktoren und suchen nach neuen Strategien, die verhindern, dass Menschen an Krebs erkranken. Wir entwickeln neue Methoden, mit denen Tumore präziser diagnostiziert und Krebspatient:innen erfolgreicher behandelt werden können. Jeder Beitrag zählt – ob in der Forschung, in der Administration oder der Infrastruktur. Das macht unsere tägliche Arbeit so bedeutungsvoll und spannend.
The German Cancer Research Center (DKFZ) is seeking for the National Center for Tumor Diseases (NCT) Heidelberg for as soon as possible a
The Section of Translational Cancer Epigenomics headed by Dr. Daniel Lipka is part of the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg. We are a dynamic international group of scientists working together with renowned national and international collaboration partners. In our group, we combine basic and translational research to discover and implement novel diagnostic and therapeutic approaches to malignant diseases. The main focus is on the analysis of epigenomic alterations occurring in premalignant and malignant cells as compared to their normal counterparts in order to understand how aberrant epigenetic programming impacts on tumor initiation and progression.
Ihre Aufgaben:
The postdoctoral researcher will work as part of an interdisciplinary team of scientists investigating the molecular defects elicited by oncogenic IDH1 mutations. IDH1 mutations are found in several malignancies and result in the production of the oncometabolite D-2- hydroxyglutarate (D2HG). D2HG was shown to alter epigenetic regulation and to support tumorigenesis. However, the prescise molecular mechanisms underlying the tumorigenic effects of mutant IDH1 remain elusive. The successful candidate will use established in vitro and in vivo models of mutant IDH1 to assess the early and cell type-specific effects of mutant IDH1 on genetic and epigenetic integrity and the resulting transcriptional aberrations that provide a fertile soil for malignant transformation. These studies will involve the use of cutting-edge technologies (EpiCyTOF, metabolomics, ACT-, ATAC-, RNA-seq, nanopore sequencing, CRISPRi and CRISPRa) to assess the molecular aberrations involved and their consequences on cell function and phenotype. Ultimately, these results might lead to the development of novel treatment options beyond inhibition of the mutant enzyme for patients with IDH1-mutant malignancies.
Ihr Profil:
We are looking for a highly motivated and ambitious postdoctoral scientist who is committed to cancer research at the crossroads of experimental hematology, epigenomics and metabolism. The candidate should be able to work independently but should also have excellent teamwork skills. Applicants must hold a Ph.D. in biology, biochemistry, biotechnology, or a related field, and have published previously in international peerreviewed journals. Expertise in molecular and cellular biology, with a specific focus on experimental hematology and/or epigenomics is advantageous. Profound knowledge of cancer biology, strong communication skills, and excellent written and oral command of English are required.
The application should include a curriculum vitae, a motivation letter, degree certificates, the expected availability date, a complete list of publications, and the names and contact information of at least two references.
Unser Angebot:
- Hervorragende Rahmenbedingungen: modernste state-of-the-art Infrastruktur und Möglichkeit zum internationalen Austausch auf Spitzenniveau
- Vergütung nach TV-L inkl. betrieblicher Altersvorsorge und vermögenswirksamer Leistungen
- 30 Tage Urlaub
- Flexible Arbeitszeiten
- Möglichkeit zur Teilzeitarbeit
- Familienfreundliches Arbeitsumfeld
- Nachhaltig zur Arbeit: Vergünstigtes Deutschland-Jobticket
- Unser betriebliches Gesundheitsmanagement bietet ein ganzheitliches Angebot für Ihr Wohlbefinden
- Entfalten Sie Ihr volles Potenzial: Zugang zum DKFZ International Postdoc Program und dem DKFZ Career Service mit gezielten Angeboten für Ihre persönliche Entwicklung fördern Ihre Talente
Sie sind interessiert?
Dr. Daniel Lipka
Telefon: +49 (0)6221/42-1613
Bewerbungen per E-Mail können leider nicht angenommen werden.
Bitte beachten Sie auch, dass wir per Post eingereichte Bewerbungen nicht zurückschicken können.
